The Effectiveness of Afatinib as First-Line Treatment in Vietnamese Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases.

Introduction: The role of afatinib in the first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC) patients has been proven through clinical trials and real-world studies. However, additional data on the effectiveness of afatinib in patients with brain metastases are lacking.

Methods: EGFR-mutant NSCLC patients with brain metastases were retrospectively reviewed across nine cancer centers in Vietnam from April 1, 2018 to June 1, 2022.

Spectrum and antimicrobial resistance in acute exacerbation of chronic obstructive pulmonary disease with pneumonia: a cross-sectional prospective study from Vietnam.

Background: Respiratory infections have long been recognized as a primary cause of acute exacerbation of chronic obstructive pulmonary disease (AE-COPD). Additionally, the emergence of antimicrobial resistance has led to an urgent and critical situation in developing countries, including Vietnam. This study aimed to investigate the distribution and antimicrobial resistance of bacteria in patients with AE-COPD using both conventional culture and multiplex real-time PCR.

Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.

Background: Afatinib is indicated for advanced-stage non-small-cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) and uncommon mutations. However, real-world studies on this topic are limited. This study aimed to evaluate afatinib as first-line therapy for locally advanced and metastatic NSCLC with uncommon EGFR mutations.

A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.

Background: This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting in Vietnam.

Methods: This retrospective study was conducted across nine hospitals in Vietnam. Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received afatinib as first-line therapy between April 2018 and June 2022 were included, and patient medical records were reviewed.

Assessing cognitive decline in Vietnamese older adults using the Montreal Cognitive Assessment-Basic (MoCA-B) and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) during the COVID-19 pandemic: A feasibility study.

The lack of cognitive assessment tools suitable for people with minimal formal education is a barrier to identify cognitive impairment in Vietnam. Our aims were to (i) evaluate the feasibility of conducting the Montreal Cognitive Assessment-Basic (MoCA-B) and Informant Questionnaire On Cognitive Decline in the Elderly (IQCODE) remotely on the Vietnamese older adults, (ii) examine the association between the two tests, (iii) identify demographic factors correlated with these tools. The MoCA-B was adapted from the original English version, and a remote testing procedure was conducted.

Catalytic degradation of acetaminophen by Fe and N Co-doped multi-walled carbon nanotubes.

An Fe and N co-doped carbon nanotube (CNT) (Fe/N-CNT) was successfully prepared using a simple hydrothermal method. CNT, Fe doped CNTs (Fe-CNT), N doped CNTs (N-CNT), and Fe/N-CNT were characterized using scanning electron microscopy, X-ray photoelectron spectroscopy, Raman spectroscopy, and zeta potential analysis. The catalytic activities of the materials were investigated via pharmaceutical (acetaminophen, ACT) degradation using persulfate (PS).

Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with mutations.

Background: There have been few studies on the efficacy of tyrosine kinase inhibitors in lung carcinomas. The purpose of this study was to evaluate the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who were positive for epidermal growth factor receptor () mutations.

Methods: This prospective analysis included 120 patients with advanced NSCLC with mutations who were administered gefitinib as the first-line therapy.

Advanced oxidative degradation of acetaminophen by carbon catalysts: Radical vs non-radical pathways.

Two representative carbon catalysts, granular activated carbon (GAC) and carbon nanotube (CNT) were selected for the degradation of acetaminophen (ACT) by persulfate (PS) activation. In this study, the materials characterization study indicated that the surface functional groups and surface area of the GAC were more abundant and larger, respectively, than the CNT. Whereas the contribution of sp and CO groups of the CNT was superior to the GAC; the structural defect levels and surface charging characteristics (pH) were similar in both.

Oxidative degradation of the antibiotic oxytetracycline by Cu@FeO core-shell nanoparticles.

A core-shell nanostructure composed of zero-valent Cu (core) and FeO (shell) (Cu@FeO) was prepared by a simple reduction method and was evaluated for the degradation of oxytetracycline (OTC), an antibiotic. The Cu core and the FeO shell were verified by X-ray diffractometry (XRD) and transmission electron microscopy. The optimal molar ratio of [Cu]/[Fe] (1/1) in Cu@FeO created an outstanding synergic effect, leading to >99% OTC degradation as well as HO decomposition within 10min at the reaction conditions of 1g/L Cu@FeO, 20mg/L OTC, 20mM HO, and pH3.

Cu@FeO core-shell nanoparticle-catalyzed oxidative degradation of the antibiotic oxytetracycline in pre-treated landfill leachate.

Novel Cu@FeO core-shell nanoparticles prepared via a simple reduction method were evaluated for degradation of oxytetracycline (OTC) in pre-treated leachate (L) (leachate treated by conventional methods). Changes in the characteristics of dissolved organic matter (DOM) in the leachate were also investigated to gain a better understanding of the effects of DOM on the performance of Cu@FeO. An excellent OTC degradation of >99% was achieved within 30 min under conditions of 1 g/L Cu@FeO, 20 mg/L OTC, 20 mM HO, and initial pH 3.